

Edgar Filing: Atara Biotherapeutics, Inc. - Form FWP

Atara Biotherapeutics, Inc.
Form FWP
January 03, 2018

Issuer Free Writing Prospectus dated January 3, 2018

Filed Pursuant to Rule 433

Relating to Preliminary Prospectus Supplement dated January 2, 2018

Registration No. 333-207876

Atara Biotherapeutics, Inc. (the **Company**) has filed a Registration Statement on Form S-3 (including a prospectus and a prospectus supplement) with the Securities and Exchange Commission (the **SEC**) for the offering to which this communication relates. Before you invest, you should read the prospectus and prospectus supplement and other documents the issuer has filed with the SEC and incorporated by reference in the prospectus and the prospectus supplement for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering may be obtained from J.P. Morgan, by mail at J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204; or from Cowen, by mail at Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 631-274-2806. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

On January 2, 2018 and January 3, 2018, an employee of the Company sent emails to three potential investors that read substantially as follows:

Happy new year [and congrats on your new role]! I've thought a lot about our meeting last year as we put together the new ATRA investor presentation attached. You [guys] may have heard that we are marketing an offering today after starting our Phase 3 studies last week. Let us know if you would like to connect with JP Morgan or Cowen to learn more.

I look forward to [catching up soon.][keeping in touch!]

Best regards,

On January 3, 2018, an employee of the Company sent an email to one potential investor that read substantially as follows:

Attached is our new investor presentation. If you're interesting in the offering today, please let me know and I would be happy to connect you to JP Morgan or Cowen.

Best regards,

On January 3, 2018, after learning of the emails and pursuant to Rule 164(c) of the Securities Act of 1933, as amended, the Company sent the following email to these potential investors:

Dear [potential investor],

My earlier email should have included the following important information:

Atara has filed a registration statement (including the base prospectus) (File No. 333-207876) and a preliminary prospectus supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the base prospectus and the preliminary prospectus supplement and other documents we filed with the SEC for more complete information about Atara and this offering. You may access these documents through the SEC's website at www.sec.gov. Alternatively, you may obtain a copy of the preliminary prospectus from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204 or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attn.: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717, by calling (631) 274-2806 or by faxing (631) 254-7140.

Sincerely,

